Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Bone Oncology"
DOI: 10.1016/j.jbo.2018.04.003
Abstract: Objectives Previous pharmacogenetics studies showed that genetic variants could be indicative of the response to chemotherapy. We aimed to investigate whether variants of FasL, MSH2, ABCC5, CASP3 and CYP3A4 are associated with the outcome after… read more here.
Keywords: chemotherapy; treatment; outcome chemotherapy; variants fasl ... See more keywords